Agios Pharmaceuticals Inc (NASDAQ:AGIO) insider Christopher Bowden sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $64.16, for a total value of $641,600.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
NASDAQ AGIO traded up $0.33 during trading on Tuesday, hitting $65.17. The stock had a trading volume of 367,672 shares, compared to its average volume of 496,141. The stock has a market capitalization of $3.80 billion, a price-to-earnings ratio of -10.81 and a beta of 2.38. Agios Pharmaceuticals Inc has a 12 month low of $41.63 and a 12 month high of $99.82.
Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Thursday, February 14th. The biopharmaceutical company reported ($1.58) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.65) by $0.07. The firm had revenue of $30.00 million for the quarter, compared to analysts’ expectations of $19.98 million. Agios Pharmaceuticals had a negative return on equity of 44.13% and a negative net margin of 366.61%. The business’s quarterly revenue was up 200.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.81) EPS. Sell-side analysts forecast that Agios Pharmaceuticals Inc will post -6.64 earnings per share for the current fiscal year.
Several equities analysts recently issued reports on AGIO shares. Zacks Investment Research lowered Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, January 2nd. BidaskClub upgraded Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, March 1st. Leerink Swann upgraded Agios Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Friday, February 15th. ValuEngine lowered Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, January 4th. Finally, Piper Jaffray Companies decreased their price objective on Agios Pharmaceuticals to $100.00 and set an “overweight” rating for the company in a research report on Thursday, February 14th. Five analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $97.86.
ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/4233619/agios-pharmaceuticals-inc-agio-insider-sells-641600-00-in-stock.html.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.
Further Reading: Insider Trading – What You Need to Know
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.